Observational analysis shows minimal residual disease implications for ovarian cancer patients, implying HRD status affects therapy decisions.
Supplementary Figure S1 Clinical management of patients in the study cohort following SLL. *Many of these patients had the HRD assay performed retroactively on archival tissue and in this case, HRD status was not known in the upfront maintenance setting to guide therapy.
No takes yet. Share an insight, caveat, or question.
Knisely et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: